In vitro and in vivo pharmacological models to assess demyelination and remyelination.
about
Mimicking white matter tract topography using core-shell electrospun nanofibers to examine migration of malignant brain tumors.Down-regulation of interleukin 7 receptor (IL-7R) contributes to central nervous system demyelination.A novel model of demyelination and remyelination in a GFP-transgenic zebrafish.Selective inhibition of CCR7(-) effector memory T cell activation by a novel peptide targeting Kv1.3 channel in a rat experimental autoimmune encephalomyelitis modelInduction of gut regulatory CD39+ T cells by teriflunomide protects against EAE.Generation of demyelination models by targeted ablation of oligodendrocytes in the zebrafish CNS.Pathophysiology of multiple sclerosis and the place of teriflunomide.Myelin restoration: progress and prospects for human cell replacement therapies.Engineering strategies to mimic the glioblastoma microenvironment.Zebrafish as a model to investigate CNS myelination.Pharmacological approaches to intervention in hypomyelinating and demyelinating white matter pathology.Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening.Lesion Expansion in Experimental Demyelination Animal Models and Multiple Sclerosis Lesions.Models for Studying Myelination, Demyelination and Remyelination.Static Magnetic Field Stimulation Enhances Oligodendrocyte Differentiation and Secretion of Neurotrophic Factors.The promyelinating properties of androstenediol in gliotoxin-induced demyelination in rat corpus callosum.Apolipoprotein E Mimetic Promotes Functional and Histological Recovery in Lysolecithin-Induced Spinal Cord Demyelination in Mice.Neuron-oligodendrocyte myelination co-culture derived from embryonic rat spinal cord and cerebral cortex.High Yield of Adult Oligodendrocyte Lineage Cells Obtained from Meningeal Biopsy.Chronic demyelination-induced seizures.Pharmacophore-based design of novel oxadiazoles as selective sphingosine-1-phosphate (S1P) receptor agonists with in vivo efficacy.Arctigenin Suppress Th17 Cells and Ameliorates Experimental Autoimmune Encephalomyelitis Through AMPK and PPAR-γ/ROR-γt Signaling.The Impact of Purinergic System Enzymes on Noncommunicable, Neurological, and Degenerative Diseases
P2860
Q30582618-112E2067-83DC-4803-B3BC-50D3D149B03DQ33709707-E0B2CC17-3FB3-4168-8AB2-23C9701C942FQ34966646-F8C02957-5FD3-41D3-875E-D05D610539DDQ36215897-CCC09730-4BB3-43D3-AFE6-8B7964EE69EDQ37337770-9FC6AF7D-2BC2-4537-8C16-4490E02E17DFQ37462421-E9F5D14D-D94B-4AF8-A572-5CBD0C1BB590Q37794267-4DFB4269-230E-450B-99EF-B495DA1578A0Q37860967-145C9343-E649-49A5-9ED3-5B0D753F69DCQ38244936-BE8706DA-4A8E-4EFF-8138-EBB98F3FAF9DQ38255026-6DCD9A32-6CC1-489B-B16B-BAA98D76997EQ38538932-88FFD50C-7B98-4F8B-A834-65FF7E5F2DFFQ38574564-1BBA2D6B-7E60-49E8-B318-4F85ECAECA5AQ38964699-D58AE465-D789-4434-BA01-7DA4F8AE7275Q39325813-9D09491E-3CA5-4113-AAA0-412F6E38E117Q41158587-0610AC6F-8822-43DD-A4A2-259D4B2EA2BAQ41197337-43698DE3-762F-4E74-A114-3AF4027C859DQ41494940-C8D0E176-074F-4669-A16C-AAAC1F2E5ADDQ41845172-B268F22B-3B1F-4A3E-8A0F-88AE02E80B88Q42692068-DD295F69-FBCE-482D-BF89-D481F8CF5D80Q46468122-A98FDAEF-633B-496D-A068-093C5BABE112Q48299333-7A79AFCA-C152-411A-9E5D-9C3517D0FD5EQ53814658-EBFE2CDB-F008-4D6C-AE39-58FE03346D92Q58787876-8178DC71-3081-41FA-95CF-D85FFD7AB7B7
P2860
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
@ast
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
@en
type
label
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
@ast
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
@en
prefLabel
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
@ast
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
@en
P2860
P356
P1476
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
@en
P2093
Jean E Merrill
P2860
P2888
P356
10.1038/NPP.2008.145
P407
P577
2008-09-17T00:00:00Z
P5875
P6179
1026628266